Novel Antidiabetic Medications in Polycystic Ovary Syndrome

Abstract

Polycystic ovary syndrome is a very common endocrine disorder prevalent in premenopausal women. Patients with polycystic ovary syndrome present with abnormal menstruation, ovulation disorders, and hyperandrogenemia. They are often accompanied by insulin resistance, metabolic disorders, and other cardiovascular abnormalities. Also, they have comorbidities, such as dyslipidemia, obesity, diabetes type 2, non-alcoholic fatty liver disease, which all influence the treatment plan. Metformin has been defined as a treatment option in patients with polycystic ovary syndrome. However, the clinical responses to metformin are limited. Thus, the need for novel treatments with a broad range of coverage for the complications is warranted. Sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, incretin analogs are novel drugs approved for treating type-2 diabetes. Because of their recorded benefit with weight loss, improved insulin resistance, and cardiovascular benefits in recent studies, they may help polycystic ovary syndrome women address the polycystic ovary syndrome-related risk of metabolic, reproductive, and psychological consequences. Limited literature is available on the safety and efficacy of these novel antidiabetic drugs in patients with polycystic ovary syndrome. Thus, this review is investigating the role and effectiveness of novel antidiabetic medication as an early therapeutic option in polycystic ovary syndrome.

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in the Treatment of Polycystic Ovary Syndrome: A Review

“…Because prior research has shown such tremendous benefits for patients with other medical conditions who are started on an SGLT2 inhibitor, there has been an interest in exploring whether this may be a novel treatment option for patients with PCOS [27][28][29][30]. In this review, we examine the effects of SGLT2 inhibitors on various outcomes in women with polycystic ovary syndrome.…”

Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?

“…These effects still deserve a greater insight, especially in the light of a possible therapeutic use in PCOS women independently of obesity. Contrariwise, other relevant aspects, such as the safety profile and tolerability of GLP-1RA or the beneficial effects on fertility in PCOS, have been more extensively treated, especially considering that possible direct or indirect reproductive effects of GLP-1 RA might require a concomitant effective contraception and a washout period before pregnancy [22,[24][25][26][27][28][29][30][31].…”